Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,601.00
Ask: 1,602.00
Change: -168.50 (-9.54%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

Wed, 01st May 2024 17:31

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Aston Martin drops after bigger than expected Q1 pretax loss

*

Haleon falls after missing Q1 revenue estimates

*

UK factories slip back into downturn as cost pressures rise

*

U.S. Fed policy decision due at 1800 GMT

May 1 (Reuters) - Britain's FTSE 100 slipped on Wednesday, led by declines in energy stocks, while investors grew cautious ahead of the U.S. Federal Reserve's policy decision later in the day, hoping for hints on its interest rate path.

The blue-chip index closed down 0.3%, while the mid-cap FTSE 250 ended off 0.2%.

Heavyweight oil and gas shares slipped 1.7% as oil prices fell over 2% to a seven-week low, weighed down by a surprise build in U.S. crude stocks, the prospect of a Middle East ceasefire agreement and persistent U.S. inflation.

As inflation remains stubbornly above the U.S. central bank’s 2% annual target, the Fed is almost certain to hold its benchmark overnight interest rate steady later on Wednesday.

However, investors await comments from Fed Chair Jerome Powell that could give clearer insights into the central bank's view on potential rate cuts.

"The question is what the Fed can say to boost hopes ... even the optimism of the FTSE 100 was no match for the familiar weight of weary expectation," said Danni Hewson, head of financial analysis at AJ Bell.

Money markets now anticipate 30 basis points (bps) of U.S. rate cuts this year, down from the initial estimate of 150 bps in 2024, according to LSEG data.

Traders expect around 38 bps of rate cuts from the Bank of England and nearly 60 bps from the European Central Bank this year, easing pressure on European stock markets compared to those in the U.S.

Meanwhile, British manufacturing fell back into contraction in April and cost pressures escalated, though the pace of decline was a little less marked than first feared, a survey showed.

In corporate updates, GSK advanced 1.9% after the drugmaker raised its full-year profit forecast and said its sales would be higher in the first half of the year.

Shell has exited China's power markets as part of CEO Wael Sawan's drive to focus on more profitable operations, taking its shares down 1.5%.

Haleon fell 2.5% after the consumer healthcare firm's first-quarter revenue missed estimates.

Dragging UK midcap stocks lower, Aston Martin slumped 6.7% after the luxury carmaker posted a bigger than expected first-quarter pretax loss. (Reporting by Pranav Kashyap, Khushi Singh and Sruthi Shankar in Bengaluru; Editing by Sherry Jacob-Phillips, Rashmi Aich and Mark Potter)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.